Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling

被引:164
作者
Schroeder, Anne [1 ]
Herrmann, Andreas [2 ]
Cherryholmes, Gregory [2 ]
Kowolik, Claudia [1 ]
Buettner, Ralf [1 ]
Pal, Sumanta [3 ]
Yu, Hua [2 ]
Mueller-Newen, Gerhard [4 ]
Jove, Richard [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Immunotherapy & Tumor Immunol, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol, Duarte, CA 91010 USA
[4] Univ Klinikum RWTH Aachen, Inst Biochem & Mol Biol, Aachen, Germany
关键词
CONSTITUTIVE ACTIVATION; INTERLEUKIN-6; GROWTH; RESISTANCE; INHIBITOR; CYTOKINE; PATHWAYS; MICROENVIRONMENT; TRANSCRIPTION-3; PLURIPOTENCY;
D O I
10.1158/0008-5472.CAN-13-0594
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Androgen receptor (AR) signaling is important for prostate cancer progression. However, androgen-deprivation and/or AR targeting-based therapies often lead to resistance. Here, we demonstrate that loss of AR expression results in STAT3 activation in prostate cancer cells. AR downregulation further leads to development of prostate cancer stem-like cells (CSC), which requires STAT3. In human prostate tumor tissues, elevated cancer stem-like cell markers coincide with those cells exhibiting high STAT3 activity and low AR expression. AR downregulation-induced STAT3 activation is mediated through increased interleukin (IL)-6 expression. Treating mice with soluble IL-6 receptor fusion protein or silencing STAT3 in tumor cells significantly reduced prostate tumor growth and CSCs. Together, these findings indicate an opposing role of AR and STAT3 in prostate CSC development. (C)2013 AACR.
引用
收藏
页码:1227 / 1237
页数:11
相关论文
共 48 条
[1]   Control of senescence by CXCR2 and its ligands [J].
Acosta, Juan C. ;
O'Loghlen, Ana ;
Banito, Ana ;
Raguz, Selina ;
Gil, Jesus .
CELL CYCLE, 2008, 7 (19) :2956-2959
[2]   Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma [J].
Adler, HL ;
McCurdy, MA ;
Kattan, MW ;
Timme, TL ;
Scardino, PT ;
Thompson, TC .
JOURNAL OF UROLOGY, 1999, 161 (01) :182-187
[3]   Relationship between serum levels of interleukin-6, tumor necrosis factor-α and bone turnover markers in prostate cancer patients [J].
Akimoto, S ;
Okumura, A ;
Fuse, H .
ENDOCRINE JOURNAL, 1998, 45 (02) :183-189
[4]   A fusion protein of the gp130 and interleukin-6Rα ligand-binding domains acts as a potent interleukin-6 inhibitor [J].
Ancey, C ;
Küster, A ;
Haan, S ;
Herrmann, A ;
Heinrich, PC ;
Müller-Newen, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (19) :16968-16972
[5]  
Birnie R, 2008, GENOME BIOL, V9, pR83
[6]   STATs in oncogenesis [J].
Bowman, T ;
Garcia, R ;
Turkson, J ;
Jove, R .
ONCOGENE, 2000, 19 (21) :2474-2488
[7]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[8]   Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer [J].
Carver, Brett S. ;
Chapinski, Caren ;
Wongvipat, John ;
Hieronymus, Haley ;
Chen, Yu ;
Chandarlapaty, Sarat ;
Arora, Vivek K. ;
Le, Carl ;
Koutcher, Jason ;
Scher, Howard ;
Scardino, Peter T. ;
Rosen, Neal ;
Sawyers, Charles L. .
CANCER CELL, 2011, 19 (05) :575-586
[9]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[10]   Prostate cancer stem cells [J].
Collins, Anne T. ;
Maitland, Norman J. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (09) :1213-1218